A Definitive, Randomized, Open Label, Crossover, Multiple Dose Study Assessing the Bioequivalence of Aripiprazole Extended-Release Injectable Suspension, (HBT009; Test) Compared to ABILIFY MAINTENAÂ® (Otsuka Pharmaceutical Co., Ltd.; Reference) in Adult Subjects with Schizophrenia and/or Schizoaffective Disorder.

HBT Labs Inc0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年5月29日

试验速览

阶段: 未知
状态: 尚未招募
发起方

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Ba/be

入排标准

入选标准

•Male or female ages 18 through 65 years, both inclusive.
•2) Subject diagnosed with schizophrenia and/or schizoaffective disorder
•as per the Diagnostic and Statistical Manual of Mental Disorders, Fifth
•Edition (DSM-5) criteria for at least 1 year and clinically stable for the
•past 4 months (non-acute) in the investigatorâ??s judgement and in the
•judgement of the treating psychiatrist if the subject is not an on-going
•subject of the investigator and based on the following objective criteria
•at the time of screening visit (Visit 1):
•Outpatient status during the entire 4-month period preceding the
•screening visit (Visit 1)
•ï??ï? Score of <= 4 on the following Positive and Negative Syndrome Scale
•(PANSS) items
•ï? Conceptual disorganization
•ï? Hallucinatory behavior
•Suspiciousness / persecution
•Unusual thought content
•A total score on the 5 PANSS items <= 18
•3) Subjects who have received documented treatment with at least three
•consecutive monthly intramuscular injection doses of ABILIFY
•MAINTENAÂ® 400 mg into the deltoid or gluteal muscle in the 3 months
•immediately prior to the screening visit (up to Day - 21). Subject who
•received prior gluteal injections will receive one additional injection
•into the deltoid muscle.
•4) Subject is on stable regimen of oral Aripiprazole 10-20 mg prior to
•screening, if not already on a stable monthly regimen of 400 mg of
•Aripiprazole Extended-Release Injectable Suspension. Such subject
•will receive at least three consecutive doses of 400 mg ABILIFY
•MAINTENAÂ® every 28 days into the deltoid muscle before
•randomization.
•5) Body mass index (BMI) >= 18 kg/m2 at screening visit (Visit 1).
•PROTOCOL # HBT009
•Protocol Version No.: 02
•Date: 17 Mar 2021
•Confidential Page 15 of 124
•6) Eligible female subject will be:
•Non-pregnant, evidenced by serum HCG tests at screening.
•Non-lactating.
•Surgically sterile or postmenopausal, defined as at least 1 year of
•spontaneous amenorrhea prior to screening visit (Visit 1), or agree to
•continue to use an accepted method of birth control during the entire
•study and for at least 4 months after the last injection received in the
•Acceptable methods of birth control are: hormonal contraceptives;
•double barrier method; intrauterine device; surgical sterility for at least
•6 months prior to screening visit (Visit 1) by tubal ligation; surgical
•sterility for at least 6 months prior to screening by hysterectomy and/or
•bilateral oophorectomy; and/or postmenopausal status (defined as at
•least 1 year without menses. Intended abstinence is not considered an
•acceptable method of birth control for this study; subject must agree to
•use an acceptable method of birth control while they become sexually
•active during the study or within 4 months after the last dose of study
另有 6 项未显示

排除标准

•Subject will not be eligible for inclusion in this study if any of the following
•criteria apply:
•1) Treatment with a second antipsychotic that is any formulation of
•aripiprazole or a metabolite or pro-drug of aripiprazole (treatment with
•a second antipsychotic other than aripiprazole, an aripiprazole
•metabolite, or an aripiprazole pro-drug is not exclusionary).
•2) Subject who has a concurrent primary psychiatric (by the DSM 5 criteria) diagnosis of intellectual development disorder and having dementia related psychosis.
•3) Subject who has attempted suicide within 1 year prior to screening or that are at significant risk of a suicide attempt based on history or the investigators judgement as per C-SSRS scale.
•4) Subject who has physically assaulted or acted substantially aggressive
•toward another person or animal or caused significant property damage
•due to aggressive behavior within 1 year prior to the screening visit
•(Visit 1) or that are at significant risk of such behaviors based on
•clinical interview.
•5) History of a moderate or severe substance use disorder (including
•alcohol and excluding only tobacco-related use disorders [caffeine is
•not a substance that is subject to a diagnosis of substance use disorder
•in DSM-5]; mild substance use disorder is not exclusionary if in the
•opinion of the investigator the mild substance use disorder will not
•interfere with the potential subjectâ??s ability to comply with protocol
•requirements) by DSM-5 criteria during the 6-month period
•immediately prior to screening or positive drug test at screening (Visit
•1) and at randomization visit.
•6) Subject is unwilling to abstain from grapefruit juice, pomelo juice,
•seville orange juice, and grape juice for at least 7 days prior to
•randomization visit and throughout the study prior to all clinical
•research unit (CRU) visits. Subject will be instructed to keep
•consumption of caffeine and caffeine-containing products consistent
•(e.g., do not decrease or increase their daily intake of caffeine).
•7) Subject with a history of neuroleptic malignant syndrome or tardive
•dyskinesia.
•8) Subject who has a concurrent primary neurological diagnosis of
•idiopathic Parkinsonâ??s disease.
•9) Subject who has any uncontrolled, unstable clinically relevant medical
•condition (e.g., cardiovascular, respiratory, hematologic,
•cerebrovascular, hepatic, renal, endocrine, immunologic or other
•medical condition), which in the judgment of the investigator and
•sponsor would interfere with the subjects ability to participate in the
•10) Clinically significant new illness in the 1 month prior to screening visit
•(Visit 1) or any hospitalization for a medical or psychiatric condition
•within 4 months of the screening visit (Visit 1).
•11) Subject who presents with any of the signs and symptoms of COVID-
•19 such as fever or chills, cough, shortness of breath, fatigue, muscle or
•body aches, headache, new loss of taste or smell, sore throat, congestion
•or sunny nose, nausea or vomiting, and diarrhea.
•12) Subject with history of organ transplantation.
•13) Malignancy within 5 years of the screening visit (Visit 1) (except for
•basal cell and squamous cell skin carci

研究者

发起方

HBT Labs Inc

相似试验

已完成

不适用

Clinical Study to Evaluate the Benefits of Saffola Oats with Diet & Exercise in Improving Cardiovascular Health on Normolipidemic Individuals

CTRI/2010/091/006124Spectrum Clinical Research Pvt Ltd60

尚未招募

不适用

A Randomized, Open-Label, Single-Center, Crossover Study of the Potential Effects of Paroxetine on the Pharmacokinetics of a Single Dose of Paliperidone Extended-Release in Healthy MeHealthy Volunteers10039628

NL-OMON29906Janssen-Cilag60

已完成

不适用

Evaluation of Pharmacokinetic/Pharmacodynamic Properties and Safety of Leucostim® Compared to Neupogen® in Healthy Adult VolunteersDiseases of the blood and blood -forming organs and certain disorders involving the immune mechanism

KCT0001861Dong-A ST56

已完成

不适用

An Open-label, Randomized, Crossover, Single Ascending Dose Pharmacokinetic Study of Continuous Subcutaneous Infusion of Lenalidomide Compared with Revlimid® Oral Capsules in Healthy Adult Male Subjectsmultiple myeloma

NL-OMON50544Starton Therapeutics16

已完成

不适用

An Open-Label, Randomized, Two-Way Crossover, Multiple Dose, Comparative Bioavailability study of Aripiprazole ER IS (400 mg) in patients with schizophrenia.

CTRI/2022/06/043537Apotex Inc58